These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21929520)

  • 1. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
    Lin GW; Yao XD; Ye DW
    BJU Int; 2011 Apr; 107(8):1326-7; author reply 1327. PubMed ID: 21929520
    [No Abstract]   [Full Text] [Related]  

  • 2. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
    Procopio G; Guadalupi V; Giganti MO; Mariani L; Salvioni R; Nicolai N; Capone F; Valdagni R; Bajetta E
    BJU Int; 2011 Jul; 108(2):223-7. PubMed ID: 21078047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
    Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
    J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.
    Agarwal N; Vogelzang NJ
    BJU Int; 2011 Jul; 108(2):227-8. PubMed ID: 21410863
    [No Abstract]   [Full Text] [Related]  

  • 5. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer.
    Keisner SV; Shah SR; Jean GW; Ussery SM; Dowell JE
    Ann Pharmacother; 2010 Oct; 44(10):1538-44. PubMed ID: 20841515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY; Lee JZ; Ha HK
    Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment.
    Schroeck FR; Skolarus TA
    Urology; 2013 Apr; 81(4):751. PubMed ID: 23465169
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma.
    Mencel PJ; DeAngelis LM; Motzer RJ
    Cancer; 1994 Apr; 73(7):1892-4. PubMed ID: 8137217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel for castration-resistant prostate cancer.
    Froehner M; Wirth MP
    Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
    [No Abstract]   [Full Text] [Related]  

  • 11. Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group.
    Witjes FJ; Debruyne FM; Fernandez del Moral P; Geboers AD
    Urology; 1989 May; 33(5):411-5. PubMed ID: 2652864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapy for prostate cancer: current topics and future perspectives.
    Suzuki H; Hinotsu S; Akaza H; Fujii Y; Kawakami S; Kihara K; Akakura K; Suzuki M; Kitamura T; Homma Y; Mizokami A
    Int J Urol; 2010 Apr; 17(4):302-13. PubMed ID: 20409228
    [No Abstract]   [Full Text] [Related]  

  • 13. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
    Takeda M; Hosaka M
    Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
    [No Abstract]   [Full Text] [Related]  

  • 14. Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
    Mahler C; Verhelst J; Denis L
    Cancer; 1993 Feb; 71(3 Suppl):1068-73. PubMed ID: 8428329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
    Matsumoto Y; Mibu H; Kagebayashi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperpolarized 1-[
    Aggarwal R; Vigneron DB; Kurhanewicz J
    Eur Urol; 2017 Dec; 72(6):1028-1029. PubMed ID: 28765011
    [No Abstract]   [Full Text] [Related]  

  • 17. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 19. Cabazitaxel for castration-resistant prostate cancer.
    Shigeta K; Miura Y; Naito Y; Takano T
    Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
    [No Abstract]   [Full Text] [Related]  

  • 20. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
    Wilkinson S; Chodak G
    Eur Urol; 2004 May; 45(5):581-4; discussion 585. PubMed ID: 15082199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.